SEC Tracker
Get the app
Person · CIK 1992352

Kathryn Guarini

Director at Regeneron Pharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$660K
Noticed on Form 144$1M
Bought on Form 4$0
Companies1

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Regeneron Pharmaceuticals REGNCommon StockDirectly603Sep 2, 2026 · Filing · EDGAR
Regeneron Pharmaceuticals REGNNon-Qualified Stock Option (right to buy)
exercise $719.37, expires Jan 2, 2035, into Common Stock
Directly1,158Sep 2, 2026 · Filing · EDGAR

Sold and noticed by quarter

Kathryn Guarini: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2025 to Q4 2026$660K$0Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $0 sold on Form 4Q3 2026: $660K noticed on Form 144Q3 2026: $660K sold on Form 4Q4 2026: $360K noticed on Form 144Q4 2026: $0 sold on Form 4Q1 2025Q3 2025Q1 2026Q3 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q4 2026—$360K
Q3 2026$660K$660K

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Regeneron Pharmaceuticals REGN · UBS Financial Services · 10b5-1 plan adopted Feb 13, 2026 · 3 notices
Oct 30, 2026400 · ~$360KOct 30, 2026Not sold yetFiling · EDGAR
Sep 2, 2026400 · ~$340KSep 2, 2026Sold as noticed Sold 400 at $850.00 on Sep 2 · $340K Form 4Filing · EDGAR
Aug 10, 2026400 · ~$320KAug 10, 2026Sold as noticed Sold 400 at $800.00 on Aug 10 · $320K Form 4Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Regeneron Pharmaceuticals REGN Director · filings 2023 to 2026 · sold $660K · $1M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Sep 2, 2026Option or RSU exercised or converted+400$719.37$288K1,003 directFiling · EDGAR
Sep 2, 2026Sale under a 10b5-1 plan−400$850.00$340K603 directFiling · EDGAR
Sep 2, 2026Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−4001,158 directFiling · EDGAR
Aug 10, 2026Option or RSU exercised or converted+400$719.37$288K1,003 directFiling · EDGAR
Aug 10, 2026Sale under a 10b5-1 plan−400$800.00$320K603 directFiling · EDGAR
Aug 10, 2026Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−4001,558 directFiling · EDGAR
Jan 2, 2026Grant or award from the company+155603 directFiling · EDGAR
Jan 2, 2026Grant or award from the company
Non-Qualified Stock Option (right to buy)
+1,9621,962 directFiling · EDGAR
Jan 2, 2025Grant or award from the company+166448 directFiling · EDGAR
Jan 2, 2025Grant or award from the company
Non-Qualified Stock Option (right to buy)
+1,9581,958 directFiling · EDGAR
Jan 2, 2024Grant or award from the company+42282 directFiling · EDGAR
Jan 2, 2024Grant or award from the company
Non-Qualified Stock Option (right to buy)
+508508 directFiling · EDGAR
Sep 8, 2023Grant or award from the company+240240 directFiling · EDGAR
Sep 8, 2023Grant or award from the company
Non-Qualified Stock Option (right to buy)
+2,7392,739 directFiling · EDGAR
All 10 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Oct 30, 2026Form 144Regeneron Pharmaceuticals REGNFiling · EDGAR
Sep 3, 2026Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Sep 2, 2026Form 144Regeneron Pharmaceuticals REGNFiling · EDGAR
Aug 12, 2026Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Aug 10, 2026Form 144Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 6, 2026Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 6, 2025Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 4, 2024Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Sep 12, 2023Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Sep 12, 2023Form 3Regeneron Pharmaceuticals REGNFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.